Whales with a lot of money to spend have taken a noticeably bearish stance on Viking Therapeutics.
Looking at options history for Viking Therapeutics VKTX we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $223,682 and 10, calls, for a total amount of $531,240.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $100.0 for Viking Therapeutics over the recent three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 783.0 with a total volume of 2,021.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $20.0 to $100.0 over the last 30 days.
Viking Therapeutics 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | SWEEP | BEARISH | 08/16/24 | $7.1 | $6.5 | $6.5 | $100.00 | $192.2K | 1.4K | 303 |
| VKTX | PUT | SWEEP | BEARISH | 09/20/24 | $12.2 | $12.2 | $12.2 | $75.00 | $74.4K | 295 | 0 |
| VKTX | CALL | SWEEP | BEARISH | 05/17/24 | $3.1 | $3.0 | $3.0 | $79.00 | $63.6K | 52 | 214 |
| VKTX | PUT | SWEEP | BEARISH | 09/20/24 | $4.1 | $4.0 | $4.1 | $55.00 | $58.3K | 305 | 200 |
| VKTX | CALL | TRADE | BULLISH | 01/17/25 | $25.9 | $23.8 | $25.06 | $70.00 | $50.1K | 597 | 28 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Viking Therapeutics's Current Market Status
- With a volume of 1,333,261, the price of VKTX is down -0.82% at $78.96.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 77 days.
What The Experts Say On Viking Therapeutics
In the last month, 1 experts released ratings on this stock with an average target price of $90.0.
- In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $90.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
